José Leal

• Economic impact of Early Intervention in Psychosis services: results from a longitudinal retrospective controlled study in England

  Tsiachristas A. et al, (2016), BMJ Open

• Models of care for the delivery of secondary fracture prevention after hip fracture: a health service cost, clinical outcomes and cost-effectiveness study within a region of England

  Judge AD. et al, (2016), Health Services and Delivery Research

• Economic burden of non-malignant blood disorders across Europe: a population-based cost study.

  Luengo-Fernandez R. et al, (2016), The Lancet Haematology, 3, e371 - e378

• Economic burden of malignant blood disorders across Europe: a population-based cost analysis.

  Burns R. et al, (2016), The Lancet. Haematology, 3, e362 - e370

• The impact of social isolation on delayed hospital discharges of older hip fracture patients and associated costs.

  Landeiro F. et al, (2016), Osteoporos Int, 27, 737 - 745

• Impact of hip fracture on hospital care costs: a population-based study.

  Leal J. et al, (2016), Osteoporos Int, 27, 549 - 558

• Impact of hip fracture on hospital care costs: a population-based study

  Leal J. et al, (2016), OSTEOPOROSIS INTERNATIONAL, 27, 549 - 558

• Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening.

  Scanlon PH. et al, (2015), Health Technol Assess, 19, 1 - 116

• UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia.

  Luengo-Fernandez R. et al, (2015), BMJ Open, 5

• The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).

  Alva ML. et al, (2015), Diabet Med, 32, 459 - 466

• IMPACT OF HIP FRACTURE ON HOSPITAL CARE COSTS: A POPULATION BASED STUDY

  Leal J. et al, (2015), OSTEOPOROSIS INTERNATIONAL, 26, S55 - S55

• Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort: does the ADDITION validation add up?

  Gray A. et al, (2014), Value Health, 17, 895 - 896

• The Burden of Health Care Costs Associated with Prostate Cancer in Ireland.

  Burns RM. et al, (2014), Value Health, 17

• Adopting an Evidence Synthesis Approach for Assessing Cost-Effectiveness of Screening Strategies for Prostate Cancer in Ireland.

  Burns RM. et al, (2014), Value Health, 17, A552 - A553

• Synthesis framework estimating prevalence of MCADD and sensitivity of newborn screening programme in the absence of direct evidence.

  Leal J. et al, (2014), J Clin Epidemiol, 67, 1131 - 1138

• Can delaying the onset of type 2 diabetes be cost-effective?

  Gray AM. et al, (2014), DIABETOLOGIA, 57, S120 - S121

• Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies.

  Leal J. et al, (2014), Int J Urol, 21, 786 - 792

• Epidemiology of fragile X syndrome: a systematic review and meta-analysis.

  Hunter J. et al, (2014), Am J Med Genet A, 164A, 1648 - 1658

• Economic burden of cancer across the European Union: a population-based cost analysis.

  Luengo-Fernandez R. et al, (2013), Lancet Oncol, 14, 1165 - 1174

• UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82

  Hayes AJ. et al, (2013), Diabetologia

• Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data.

  Leal J. et al, (2013), Diabetes Care, 36, 1541 - 1546

• UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?

  Luengo-Fernandez R. et al, (2012), Eur J Neurol, 19, 149 - 154

• An improved model to estimate lifetime health outcomes of patients with type 2 diabetes using 30-year follow-up data from the United Kingdom prospective diabetes study

  Hayes AJ. et al, (2011), DIABETOLOGIA, 54, S8 - S8

• Risk equations to predict life expectancy of people with Type 2 diabetes mellitus following major complications: a study from Western Australia.

  Hayes AJ. et al, (2011), Diabet Med, 28, 428 - 435

• Cost of dementia in the pre-enlargement countries of the European Union.

  Luengo-Fernandez R. et al, (2011), J Alzheimers Dis, 27, 187 - 196

• DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

  Wordsworth S. et al, (2010), Eur Heart J, 31, 926 - 935

• Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention--Health Policy, in Venice, Italy, on 25 October, 2008.

  Atella V. et al, (2009), Atheroscler Suppl, 10, 3 - 21

• Development of life-expectancy tables for people with type 2 diabetes.

  Leal J. et al, (2009), Eur Heart J, 30, 834 - 839

• Estimating the cost of complications of diabetes in Australia using administrative health-care data.

  Clarke P. et al, (2008), Value Health, 11, 199 - 206

• Eliciting expert opinion for economic models: an applied example.

  Leal J. et al, (2007), Value Health, 10, 195 - 203

• Cost of cardiovascular diseases in the United Kingdom.

  Luengo-Fernández R. et al, (2006), Heart, 92, 1384 - 1389

• Is DNA testing for hypertrophic cardiomyopathy cost-effective?

  Wordsworth S. et al, (2006), JOURNAL OF MEDICAL GENETICS, 43, S30 - S30

• Economic burden of cardiovascular diseases in the enlarged European Union.

  Leal J. et al, (2006), Eur Heart J, 27, 1610 - 1619

• Regional differences in the frequency of the c.985A>G ACADM mutation: findings from a meta-regression of genotyping and screening studies

  Leal JJ. et al, Clinical Genetics: an international journal of genetics and molecular medicine

• Perceptions of Risks for Diabetes-Related Complications in Type 2 Diabetes Populations. A Systematic Review.

  Rouyard T. et al, Diabetic Medicine

• How important is parameter uncertainty around the UK EQ-5D-3L value set when estimating treatment effects?

  Gray A. et al, Joint meeting of the Health Economists' Study Group and the Collège des économistes de la santé Aix-en-Provence, France, 11-13 January 2012

• Economic burden of bladder cancer across the European Union

  Leal J. et al, European Urology

• Cost-effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: a population based study

  leal J. et al, Journal of Bone and Mineral Research

• Cost effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let’s Prevent Diabetes cluster randomised controlled trial

  Leal J. et al, BMJ Open

• Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis

  Hawley S. et al, Journal of Bone and Mineral Research

Recent Publications

• Economic impact of Early Intervention in Psychosis services: results from a longitudinal retrospective controlled study in England

  Tsiachristas A. et al, (2016), BMJ Open

• Models of care for the delivery of secondary fracture prevention after hip fracture: a health service cost, clinical outcomes and cost-effectiveness study within a region of England

  Judge AD. et al, (2016), Health Services and Delivery Research

• Economic burden of non-malignant blood disorders across Europe: a population-based cost study.

  Luengo-Fernandez R. et al, (2016), The Lancet Haematology, 3, e371 - e378

• Economic burden of malignant blood disorders across Europe: a population-based cost analysis.

  Burns R. et al, (2016), The Lancet. Haematology, 3, e362 - e370

• The impact of social isolation on delayed hospital discharges of older hip fracture patients and associated costs.

  Landeiro F. et al, (2016), Osteoporos Int, 27, 737 - 745